As of 2025-09-17, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (38.15) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.67 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -2384.7%.
The range of the Relative Valuation is (37.13) - (38.52) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.2x - 18.8x | 18.6x |
| Forward P/E multiples | 18.1x - 19.3x | 18.6x |
| Fair Price | (37.13) - (38.52) | (38.15) |
| Upside | -2323.3% - -2406.8% | -2384.7% |
| Date | P/E |
| 2025-09-10 | -0.78 |
| 2025-09-09 | -0.76 |
| 2025-09-08 | -0.78 |
| 2025-09-05 | -0.80 |
| 2025-09-04 | -0.67 |
| 2025-09-03 | -0.72 |
| 2025-09-02 | -0.69 |
| 2025-08-29 | -0.55 |
| 2025-08-28 | -0.38 |
| 2025-08-27 | -0.33 |
| 2025-08-26 | -0.32 |
| 2025-08-25 | -0.30 |
| 2025-08-22 | -0.31 |
| 2025-08-21 | -0.30 |
| 2025-08-20 | -0.30 |
| 2025-08-19 | -0.30 |
| 2025-08-18 | -0.32 |
| 2025-08-15 | -0.31 |
| 2025-08-14 | -0.30 |
| 2025-08-13 | -0.28 |
| 2025-08-12 | -0.29 |
| 2025-08-11 | -0.27 |
| 2025-08-08 | -0.29 |
| 2025-08-07 | -0.29 |
| 2025-08-06 | -0.29 |
| 2025-08-05 | -0.28 |
| 2025-08-04 | -0.30 |
| 2025-08-01 | -0.29 |
| 2025-07-31 | -0.30 |
| 2025-07-30 | -0.31 |
| 2025-07-29 | -0.30 |
| 2025-07-28 | -0.31 |
| 2025-07-25 | -0.32 |
| 2025-07-24 | -0.32 |
| 2025-07-23 | -0.35 |
| 2025-07-22 | -0.30 |
| 2025-07-21 | -0.30 |
| 2025-07-18 | -0.28 |
| 2025-07-17 | -0.29 |
| 2025-07-16 | -0.30 |
| 2025-07-15 | -0.31 |
| 2025-07-14 | -0.31 |
| 2025-07-11 | -0.30 |
| 2025-07-10 | -0.33 |
| 2025-07-09 | -0.30 |
| 2025-07-08 | -0.30 |
| 2025-07-07 | -0.30 |
| 2025-07-03 | -0.31 |
| 2025-07-02 | -0.29 |
| 2025-07-01 | -0.30 |